Eupraxia Pharmaceuticals (EPRX) to Release Quarterly Earnings on Wednesday

Key Points

• Eupraxia Pharmaceuticals will report quarterly results before the market opens on Wednesday, May 6, with analysts forecasting earnings of ($0.22) per share; the company missed the prior quarter (reported ($0.37) vs. ($0.16) expected) and analysts project about -$1 EPS for both the current and next fiscal years.
• Analyst sentiment is mixed: MarketBeat shows an average rating of "Moderate Buy" with a consensus price target of $15, while individual broker notes range from Zacks' "strong sell" to Cantor Fitzgerald's $19 "overweight."
• The stock opened at $7.11 with a market capitalization of roughly $429.7 million and a 12‑month range of $3.67 to $9.32, highlighting recent volatility.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) is expected to issue its results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.21). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Trading Down 1.4%

NASDAQ EPRX opened at $7.11 on Wednesday. The stock has a market capitalization of $429.66 million, a price-to-earnings ratio of -6.90 and a beta of 1.55. The business's 50 day moving average is $7.45 and its two-hundred day moving average is $7.17. Eupraxia Pharmaceuticals has a 12-month low of $3.67 and a 12-month high of $9.32.

Analyst Ratings Changes

A number of brokerages recently weighed in on EPRX. Zacks Research lowered Eupraxia Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Tuesday, March 17th. William Blair initiated coverage on Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They issued an "outperform" rating for the company. Cantor Fitzgerald upped their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an "overweight" rating in a research note on Thursday, January 15th. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, April 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $15.00.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its position in Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock worth $1,125,000 after purchasing an additional 59,683 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company's stock valued at $108,000 after purchasing an additional 16,017 shares during the last quarter. Bank of America Corp DE grew its holdings in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock valued at $72,000 after purchasing an additional 10,059 shares during the last quarter. UBS Group AG grew its holdings in Eupraxia Pharmaceuticals by 155.4% in the third quarter. UBS Group AG now owns 95,756 shares of the company's stock valued at $565,000 after purchasing an additional 58,257 shares during the last quarter. Finally, Raymond James Financial Inc. grew its holdings in Eupraxia Pharmaceuticals by 173.3% in the third quarter. Raymond James Financial Inc. now owns 33,373 shares of the company's stock valued at $197,000 after purchasing an additional 21,161 shares during the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.